

PACKMaN

INVESTIGATIONAL MEDICINAL PRODUCT DOSSIER

Ketamine 15mg/ml (2ml ampoules containing 1ml)

Morphine 10mg/ml (2ml ampoules containing 1ml)

Version No.:	1.1
Date:	16 October 2020
Sponsor:	The University of Warwick
Full Title:	Paramedic Analgesia Comparing Ketamine and MorphiNe in trauma : PACKMaN
EudraCT No:	2020-000154-10

TABLE OF CONTENTS

TABLE OF CONTENTS	2
INTRODUCTION	4
A. KETAMINE 15MG/ML (2ML AMPOULES CONTAINING 1ML)	5
S Drug Substance	5
P investigational Medicinal Product Under Test	5
P.1 Description and Composition	5
P.2 Pharmaceutical Development	6
P.3 Manufacture.....	6
P.3.1 Manufacturer(s)	6
P.3.2 Batch Formula	7
P.3.3 Description of Manufacturing Process and Process Controls	7
P.3.4 Control of Critical Steps and Intermediates	8
P.3.5 Process Validation and/or Evaluation	8
P.4 Control of Excipients.....	8
P.4.1 Specifications	8
P.4.5 Excipients of Animal or Human Origin	8
P.4.6 Novel Excipients	8
P.5.1 Specifications	9
P.5.2 Analytical Procedures.....	9
P.5.3 Validation of Analytical Procedures	12
P.5.3.1 Validation of the Test for Bioburden	13
P.5.3.2 Validation of the Test for Sterility	13
P.5.3.3 Validation of the Test for Bacterial Endotoxins.....	13
P.5.4 Batch Analysis.....	14
P.7 Container Closure System	14
P.8 Stability	14
B. MORPHINE 10MG/ML (2ML AMPOULES CONTAINING 1ML)	17
S Drug Substance	17
P Investigational Medicinal Product Under Test	17
P.1 Description and Composition	17
P.2 Pharmaceutical Development	18
P.3 Manufacture.....	18

P.3.1 Manufacturer(s)	18
P.3.2 Batch Formula	18
P.3.3 Description of Manufacturing Process and Process Controls	18
P.3.4 Control of Critical Steps and Intermediates	19
P.3.5 Process Validation and/or Evaluation	19
P.4 Control of Excipients.....	20
P.4.1 Specifications	20
P.4.5 Excipients of Animal or Human Origin	20
P.4.6 Novel Excipients	20
P.5 Control of the Drug Product.....	21
P.5.1 Specifications	21
P.5.2 Analytical Procedures.....	22
P.5.3 Validation of Analytical Procedures	26
P.5.3.1 Validation of the Test for Bioburden	26
P.5.3.2 Validation of the Test for Sterility	26
P.5.3.3 Validation of the Test for Bacterial Endotoxins.....	27
P.5.4 Batch Analysis.....	27
P.7 Container Closure System	28
P.8 Stability	28
2.1.A Appendices	31
2.1.A.1 Facilities and Equipment	31
2.1.A.2 Adventitious Agents Safety Evaluation	31
2.1.A.3 Novel excipients	31
2.1.A.4 Solvents for Reconstitution and Diluents.....	31
2.1.A.5 Labelling.....	32
2.1.A.6 Attachments.....	33
Version Control	34

INTRODUCTION

The PACKMaN trial is a multi-centre, pragmatic, controlled, blinded trial investigating if ketamine is superior to morphine at reducing pain in adults with severe pain due to acute traumatic injury.

The investigational medicinal products are ketamine 15mg/ml solution for injection (2ml ampoules containing 1ml) and morphine 10mg/ml solution for injection (2ml ampoules containing 1ml). All investigational medicinal products are manufactured according to EU GMP and labelled according to Annex 13 guidelines in a trial-specific way.

A. KETAMINE 15MG/ML (2ML AMPOULES CONTAINING 1ML)

S DRUG SUBSTANCE

Ketamine hydrochloride Ph. Eur. is manufactured by CU Chemie Uetikon GmbH.

CU Chemie Uetikon GmbH hold a Certificate of Suitability for the manufacture of Ketamine Hydrochloride, No. R1-CEP 2005-281-Rev 00 (refer to Attachment 2).

Name of holder:

CU CHEMIE UETIKON GMBH
Raiffeisenstrasse 4
Germany-77933 Lahr

Site of production:

CU CHEMIE UETIKON GMBH
Raiffeisenstrasse 4
Germany-77933 Lahr

P INVESTIGATIONAL MEDICINAL PRODUCT UNDER TEST

P.1 Description and Composition

The product contains Ketamine hydrochloride as the active pharmaceutical ingredient, in aqueous solution at a concentration of 17.4mg in 1ml, equivalent to 15mg per 1mL of Ketamine base. The product is presented as a sterile, clear, colourless solution as below.

KET01 - 1mL in a 2mL Type 1 glass ampoule

One 1mL dose of Ketamine 15mg/mL Solution contains the following:

Component	Function	Amount in 5mL	Ref to Std
Ketamine hydrochloride	Therapeutic agent	17.4mg ⁺	Ph. Eur
Sodium Chloride	Osmotic agent	9mg	Ph. Eur
Distilled water	Solubiliser, Vehicle	To 1mL	Ph. Eur

⁺ = adjusted for purity and loss on drying

P.2 Pharmaceutical Development

P.2.1 Formulation Development

Ketamine hydrochloride is commonly used in injections and infusions (ref Katalar PL 00057/0529) due to the increased aqueous solubility over Ketamine base. Sodium chloride is required as an osmotic agent for injections.

P.2.2. Overages

No overages have been applied to the product. The amount of Ketamine hydrochloride is adjusted for the hydrochloride salt and the potency of the batch of material (purity by assay and water content) to provide a dose of Ketamine base in the solution at 15mg in 1mL.

P.2.3. Physicochemical and biological properties

Ketamine is a cyclohexanone derivative with analgesic and anesthetic properties. Although its mechanism of action is not well understood, ketamine appears to exert complex pharmacological actions including inhibition of biogenic amine uptake, binding to opioid receptors, and inhibition of N-methyl D-aspartate (NMDA) receptors. Because of the involvement of spinal NMDA receptors in the process of central sensitization, this agent may reduce pain perception and induce sedation.

(https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C61797)

P.3 Manufacture

P.3.1 Manufacturer(s)

The manufacture of the ampoules will be carried out by:

Calderdale and Huddersfield NHS Foundation Trust trading as Huddersfield Pharmacy Specials (HPS)

Manufacturing site: Acre Mills, Gate 2, School Street West, Lindley, Huddersfield, HD3 3ET, UK

MIA(IMP) Authorisation: MIA(IMP) 19055

A copy of the MIA (IMP) authorisation has been included as part of this submission (Attachment 1).

P.3.2 Batch Formula

Batch size: Approximately 2 litres of solution will be prepared per batch.

1 litre contains:


Excipient	Amount
Ketamine hydrochloride	17.2952g
Sodium Chloride	9.0g
Water for injection	q.s.1L


P.3.3 Description of Manufacturing Process and Process Controls

Description

1. Add water for injection to the main vessel
2. Add the Ketamine hydrochloride and mix until dissolved
3. Add the sodium chloride and mix until dissolved
4. Make to volume with water for injection
5. Record the pH
6. Fill into ampoules
7. Sterilise by autoclave

Flow chart





P.3.4 Control of Critical Steps and Intermediates

No critical steps have been identified in the manufacturing process.

A visual check of the solution is performed after mixing to ensure full dissolution of the API/excipient prior to continuation to the next step.

The pH of the final solution is checked to verify that it is within the required range of pH4.0 – 5.0

P.3.5 Process Validation and/or Evaluation

Process Validation is not required at this stage of the application.

The method of sterilization by autoclave cycle has been fully validated for the proposed container closure system. Sterility is assured by QC evaluation of the Drug Product as per pharmacopoeia.

P.4 Control of Excipients

P.4.1 Specifications

Water for Injection in bulk is produced by the drug product manufacturer by distillation. The water system is qualified and monitored on a scheduled basis in accordance with EU GMP and the Ph. Eur.

Excipient	Reference to standard
Sodium Chloride	Ph Eur

P.4.5 Excipients of Animal or Human Origin

Excipients are not derived from animal sources and hence there is no BSE/TSE risk regarding the used materials.

P.4.6 Novel Excipients

Not applicable

P.5 Control of the Drug Product

P.5.1 Specifications

Test	Method	Acceptance Criteria
Examination	Visual Inspection	A clear, colourless to pale yellow solution free from particulate contamination
pH	BP Appendix V L (Ph Eur 2.2.3)	3.5 – 5.5
Identification of Ketamine	HPLC (Assay of Ketamine and Known/Unknown Related substances) BP Appendix III D (Ph Eur 2.2.29)	1. Retention time comparison with a reference standard 2. UV Spectral Comparison with a reference standard
Assay of Ketamine		14.25 – 15.75mg/mL
Known/Unknown Related Substances		Not greater than 0.5% wrt API With not more than one >0.25% wrt API
Total Known/Unknown Related Substances (% wrt API)		Not greater than 1.0% wrt API
Sterility Test	BP Appendix XVI A (Ph Eur 2.6.1)	Pass
BET	BP Appendix XIV C (Ph Eur 2.6.14)	<17.0 EU/mg
Sub-visible particle count	BP Appendix XIII A (Ph Eur 2.9.19)	10µm ≤6000/container 25µm ≤600/container

P.5.2 Analytical Procedures

Ph. Eur. and BP methods are used throughout with the following exception.

Assay of Ketamine hydrochloride, known and unknown related substances by HPLC-UV

Note with respect to the HPLC method

In the future, chromatographic conditions may be adjusted to attain or optimize system performance and suitability. Equivalent chromatographic columns and related equipment

may be substituted if found suitable. Quantities proportionally larger or smaller than the specified weights and volumes of samples, standards, and reagents may be used. Subsequent steps, such as dilution, may be adjusted accordingly to yield concentrations equivalent to those specified. As required, calculation of results may be corrected to account for changes in weights and/or volumes. However, changes to the method may only be incorporated after successful completion of the applicable validation.

Equipment: A suitable HPLC system fitted with a Diode Array UV detector.

Chromatographic conditions:

Column	ACE Excel 3 Super C18 125 x 4.6 mm, Part number: EXL-1111-1246u
Mobile phase	Dissolve 1.36 g potassium dihydrogen phosphate in 650mL water and add 1 mL triethylamine and 350 mL acetonitrile. Mix well and sonicate for 10 minutes before use.
Flow Rate	1.5 mL/min
Sample volume	15 uL
Oven Temperature	40°C
UV Wavelength	248 nm
Run Time	13 minutes for standards and 30 minutes for samples
Peak width	0.5
Bandwidth	1
Wash Solvent	50% Methanol

Run mobile phase for at least 15 minutes to allow column to equilibrate.

Preparation of Calibration Standard Solution:

Weigh accurately 0.15 - 0.19 g of ketamine hydrochloride reference standard into a 50 mL volumetric flask and dissolve in water, dilute to volume with water.

To be prepared in duplicate to provide a recovery standard

Preparation of Test Sample Solution (0.3%w/v):

Add by pipette 2.0 mL of well mixed sample into a 10 mL volumetric flask and dissolve in water. Dilute to volume with water and mix well.

Preparation of 0.5% Limit Test Solution:

Dilute 1.0mL of Calibration Standard Solution to 200mL with water.

Preparation of 0.25% Limit Test Solution:

Dilute 5.0mL of 0.5% Limit Test Solution to 10mL with water.

Preparation of 0.1% Limit Test Solution:

Dilute 2.0mL of 0.5% Limit Test Solution to 10mL with water.

Analytical Solution Stability:

Standard solutions are stable for 21 days when stored at ambient temperature.

Calculations

All standard weights are corrected for purity

A factor is shown in each calculation to convert to the correct salt form.

Corrected standard weight for Ketamine (mg/mL) =

$$\frac{\text{Standard weight} \times 1000 \times \text{Purity} \times 237.7}{50 \times 100 \times 274.2}$$

Calculation of Ketamine =

$$\frac{\text{Corrected Standard weight} \times \text{area ketamine in sample} \times 100}{\text{Area ketamine in std}} = \text{mg/mL ketamine}$$

Calculation of Ketamine Related Substances =

$$\frac{\text{Corrected Standard weight} \times \text{area related substance in sample} \times 1000}{\text{Area ketamine in std} \times 5} = \% \text{w/v ketamine}$$

The expected retention time for each analyte is below:

Component	Approx. Retention Time
Ketamine	9.3 mins
Impurity A	10.3 mins

Figure P.5.2.1: Chromatogram of atypical Calibration Standard injection




Figure P.5.2.2: Chromatogram of a typical test sample injection:





Figure P.5.2.3 Baseline scaled chromatogram of a spiked sample demonstrating the retention time of known impurity.



P.5.3 Validation of Analytical Procedures

The validation of analytical procedures is not required as they are taken from the European Pharmacopeia and British Pharmacopeia, if not stated otherwise below.

Parameter/Assessment	Acceptance criteria	Result
Specificity	<ul style="list-style-type: none"> The peak due to Ketamine hydrochloride must be free from interference The minimum resolution between Ketamine hydrochloride and any other peak must be >1.5. Peak purity of Ketamine hydrochloride in all unadulterated samples should be between 98.0 – 102.0 % of the standard. The UV spectra of Ketamine hydrochloride must be concurrent between sample and standard. 	Specificity confirmed
Linearity (Samples of Ketamine hydrochloride at 0.05-120%)	Correlation Co-efficient $R^2 > 99.9\%$	$R^2 = 100.00$
Accuracy	Recovered amounts should be as below:	Accuracy confirmed for

(spiked samples 0.05, 80, 100 and 120%; 6 repeats)	At 0.05%, 0.1%, within 85.0 – 115.0% At 1.0% within 90.0 – 110.0% At 80,100, 120% - within 98.0-102.0%	Ketamine hydrochloride
Precision (repeatability) a) 6 replicates tested in duplicate, b) 10 repeats of same sample	a) %RSD \leq 2.0 b) %RSD \leq 1.0	a) 0.8%RSD b) 0.1%RSD

Limit of Detection and Quantification of Ketamine hydrochloride

Ketamine can be easily quantified at 0.05% of nominal concentration. Signal:Noise Ratios below are taken from the accuracy solutions at 0.05% which is below the reporting threshold of the specification.

Identification	Signal to noise ratio			Mean
	Injection 1	Injection 2	Injection 3	
0.05% accuracy 1	10.3	11.3	11.3	11.5
0.05% accuracy 2	12.3	10.3	11.0	
0.05% accuracy 3	11.3	12.2	13.1	
Acceptance Criteria: >10				
All acceptance criteria met.				

Intermediate Precision is not required at this stage of the application.

P.5.3.1 Validation of the Test for Bioburden

Not required at this stage of the application.

P.5.3.2 Validation of the Test for Sterility

The method validation report has been included as Attachment 5.

P.5.3.3 Validation of the Test for Bacterial Endotoxins

The method validation report has been included as Attachment 6.

P.5.4 Batch Analysis

The below batch is representative of a batch intended for use in the proposed clinical trial.

Test	Batch no:	300218X
	Manufacturing Date:	18Feb2020
	Batch size:	2.5L (567 units sub batch)
	Acceptance Criteria	Result
Examination	A clear, colourless to pale yellow solution free from particulate contamination	Complies
pH	3.5 – 5.5	4.5
Identification of Ketamine	1. Retention time comparison with a reference standard 2. UV Spectral Comparison with a reference standard	1. Complies 2. Complies
Assay of Ketamine	14.25 – 15.75mg/mL	
Known/Unknown Related Substances	Not greater than 0.5% wrt API With not more than one >0.25% wrt API	Complies
Total	Not greater than 1.0% wrt API	Complies
Sterility Test	Pass	Pass
BET	<17.0 EU/mg	
Particle counts	10µm ≤6000/container 25µm ≤600/container	9.1 0.4

P.7 Container Closure System

Primary Packaging

2ml Type 1 Fiolax clear Form D glass ampoules according to Ph. Eur. 3.2.1.

P.8 Stability

Storage Conditions:

Store in a dry place. Protect from light.

Shelf-life:

Based on historical data of existing ketamine products an initial expiry of 12 months will be assigned for Ketamine 15mg/mL in 2mL glass ampoules containing 1.2mL with a rolling program to extend the shelf-life to 18 months (for subsequent batches) from data available via an ongoing stability study plan (see ‘Shelf-life Extension Program’ below).

The preparation is to be used immediately after opening so no in-use stability data will be presented.

Samples from three batches of ampoules will be included in a supporting ongoing stability study program with analysis performed as described below. Data from this study will be reviewed at each time point to verify the predicted shelf life of 18 months.

Stability control

The stability study protocol has been designed to provide assurance of ongoing stability:

Product Code	KET01S	Batch number	300218X	DOM	18Feb2020
Product Name	Ketamine injection				
Strength	15mg/mL	Pack size	1mL in 2mL ampoule		
Aim of Study					
Development batch to perform stability study in support of Packman Clinical Trial C013					
Duration of Stability Study	18M				
Timepoints required	0,1,2,3,6,9,12,14,18M				
Storage Condition(s)	25°C/60%RH, 30°C/65%RH, 40°C/75%RH				

Testing Requirements

Test	Description
(a)	Physical (appearance)
(b)	pH
(c)	Assay of Ketamine and Related Substances
(d)	Sterility
(e)	Particle Counts
(f)	Bacterial Endotoxins

Timepoints No. of samples to pull (testing requirements in brackets)

	T=0	1M	2M	3M	6M	9M	12M	14M	18M
5°C	97 (a – f)								
25°C				12 (a–c)	12 (a–c)	12 (a–c)	12 (a–c)	12 (a–c)	82 (a–e)
30°C				12 (a–c)	12 (a–c)	12 (a–c)	12 (a–c)		
40°C		12 (a–c)	12 (a–c)	12 (a–c)	12 (a–c)				

Specifications are as stated in P.5.1

Shelf-life Extension Program

The initial 12 months expiry may be extended during the Clinical Trial based on the results of the stability study performed on a test batch. In the extension, extrapolation will be used requiring real-time data of ketamine assay and degradation products before an expiry is set as follows:

Real-time stability data available	Proposed shelf-life
3 months at accelerated conditions (40°C/75%RH)	12 months
14 months at ambient temperatures (25°C/60%RH)	14 months
18 months at ambient temperatures (25°C/60%RH)	18 months

The specification used will be the same as the Release analysis. Shelf-life will not be extended if the trend analysis performed according to ICH Q1E shows that the specification at the end of shelf-life is not met.

Stability results available at the time of submission are included in Attachment 9.

B. MORPHINE 10MG/ML (2ML AMPOULES CONTAINING 1ML)

S DRUG SUBSTANCE

Morphine sulfate Ph. Eur. is manufactured by Johnson Matthey, now known as MACFARLAN SMITH LIMITED GB EH11 2QA Edinburgh.

Johnson Matthey manufacture Morphine sulfate Ph. Eur. in accordance with EDQM Certificate of Suitability No. R1-CEP 2001-239-Rev 06, a copy of which is included in the application (Attachment 3).

P INVESTIGATIONAL MEDICINAL PRODUCT UNDER TEST

P.1 Description and Composition

The product contains Morphine sulfate as the active pharmaceutical ingredient, in aqueous solution at a concentration of 10mg in 1ml. The product is presented as a sterile, clear, colourless solution as below.

MOR19S - 1mL in a 2mL Type 1 glass ampoule

One 1mL dose of Morphine sulfate 10mg/mL solution contains the following:

Component	Function	Amount in 5mL	Ref to Std
Morphine sulfate	Therapeutic agent	10mg ⁺	Ph. Eur
Sodium Chloride	Osmotic agent	9mg	Ph. Eur
Disodium edetate	Chelating agent	1mg	Ph. Eur
Distilled water	Solubiliser, Vehicle	To 1mL	Ph. Eur

⁺ = adjusted for purity and loss on drying

P.2 Pharmaceutical Development

Morphine sulfate is commercially available as an injection in various strengths and pack sizes. It was originally licenced by Bristol Laboratories Limited and a number of generic equivalents are available.

Morphine is one of a group of medicines called opioid analgesic, which act at specific points in the brain and nervous tissue to alter the patient's sensitivity to pain.

P.3 Manufacture

P.3.1 Manufacturer(s)

The manufacture of the ampoules will be carried out by:

Calderdale and Huddersfield NHS Foundation Trust trading as Huddersfield Pharmacy Specials (HPS)

Manufacturing site: Acre Mills, Gate 2, School Street West, Lindley, Huddersfield, HD3 3ET, UK

MIA(IMP) Authorisation: MIA(IMP) 19055

A copy of the MIA(IMP) authorisation has been included as part of this submission (Attachment 1).

P.3.2 Batch Formula

Batch size: Approximately 2 litres of solution will be prepared per batch.

1 litre contains:

Excipient	Amount
Morphine sulfate	10.0g
Sodium Chloride	9.0g
Disodium edetate	1.0g
Distilled water	q.s.1L

P.3.3 Description of Manufacturing Process and Process Controls

Description

1. Add water for injection to the main vessel
2. Sparge the vessel with nitrogen throughout
3. Add the Morphine Sulfate and mix until dissolved
4. Add the sodium chloride and mix until dissolved
5. Add the disodium edetate and mix until dissolved
6. Make to volume with water for injection
7. Record the pH
8. Fill into ampoules
9. Sterilise by autoclave

Flow chart

Sterile Manufacture

	In Process Controls	Environment
The Excipient and API are weighed	Check of balance	Grade C
↓		
Nitrogen sparge throughout	Check for bubbles/flow meter reading	Grade C
↓		
Dissolution of API in WFI	Visual check dissolved	Grade C
↓		
Dissolution of excipient in WFI	Visual check dissolved	Grade C
↓		
Make to Volume in WFI	Visual volume check	Grade C
↓		
Verify pH is in range 4.0 – 5.0	Check of pH meter	Grade C
↓		
Dissolution of excipient in WFI	Visual check dissolved	Grade C
↓		
Sterile filtration 0.2 µm	Pre-filtration bioburden (<10cfu/100 ml) Filter integrity test	Grade A
↓		
Dispensing	Filling weight (1.3mL ± 0.1mL per ampoule)*	Grade A
↓		
Terminal sterilisation	Check of cycle printout	
↓		
Visual inspection	Visual inspection	
↓		
Bulk Packaging		

P.3.4 Control of Critical Steps and Intermediates

No critical steps have been identified in the manufacturing process.

A visual check of the solution is performed after mixing to ensure full dissolution of the API/excipient prior to continuation to the next step.

The pH of the final solution is checked to verify that it is within the required range of pH4.0 – 5.0

P.3.5 Process Validation and/or Evaluation

Process Validation is not required at this stage of the application.

The method of sterilization by autoclave cycle has been fully validated for the proposed container closure system. Sterility is assured by QC evaluation of the Drug Product as per pharmacopoeia.

P.4 Control of Excipients

P.4.1 Specifications

Water for Injection in bulk is produced by the drug product manufacturer by distillation. The water system is qualified and monitored on a scheduled basis in accordance with EU GMP and the Ph. Eur.

Excipient	Reference to standard
Sodium Chloride	Ph Eur
Disodium edetate	Ph Eur

P.4.5 Excipients of Animal or Human Origin

Excipients are not derived from animal sources and hence there is no BSE/TSE risk regarding the used materials.

P.4.6 Novel Excipients

Not applicable

P.5 Control of the Drug Product

P.5.1 Specifications

Test	Method	Acceptance Criteria
Examination	Visual Inspection	A clear, colourless to pale yellow solution free from particulate contamination
pH	BP Appendix V L (Ph Eur 2.2.3)	2.5 – 6.5
Identification of Morphine sulfate	HPLC (Assay of Ketamine and Known/Unknown Related substances) BP Appendix III D (Ph Eur 2.2.29)	1. Retention time comparison with a reference standard 2. UV Spectral Comparison with a reference standard
Assay of Morphine sulfate		9.5 – 10.5mg/mL
Codeine (Impurity A)		Not greater than 0.5% wrt API
Any other single Known Related Substance		Not greater than 0.2% wrt API
Any other single Unknown Related Substance		Not greater than 0.2% wrt API
Total Known/Unknown Related Substances (% wrt API)		Not greater than 2.0% wrt API
Sterility Test	BP Appendix XVI A (Ph Eur 2.6.1)	Pass
BET	BP Appendix XIV C (Ph Eur 2.6.14)	<17.0 EU/mg
Sub-visible particle count	BP Appendix XIII A (Ph Eur 2.9.19)	10µm ≤6000/container 25µm ≤600/container

P.5.2 Analytical Procedures

Ph. Eur. and BP methods are used throughout except where specified below:

Assay of Morphine sulfate, known and unknown related substances by HPLC-UV

Note with respect to the HPLC method

In the future, chromatographic conditions may be adjusted to attain or optimize system performance and suitability. Equivalent chromatographic columns and related equipment may be substituted if found suitable. Quantities proportionally larger or smaller than the specified weights and volumes of samples, standards, and reagents may be used. Subsequent steps, such as dilution, may be adjusted accordingly to yield concentrations equivalent to those specified. As required, calculation of results may be corrected to account for changes in weights and/or volumes. However changes to the method may only be incorporated after successful completion of the applicable validation.

Equipment: A suitable HPLC system fitted with a Diode Array UV detector.

Analytical column : Ace Excel 5 super C18 250 x 4.6mm

Chromatographic Conditions

Mobile phase A (1L)	1.35g sodium acetate trihydrate in water adjusted to pH 4.0 with glacial acetic acid					
Mobile phase B	Acetonitrile					
Gradient						
Time (min)	0	0.5	6.0	7.5	8.0	10.0
%B	7	7	20	20	7	7
Flow Rate	1.5 mL/min					
Sample volume	50µL					
Oven Temperature	40°C					
UV Wavelength	285 nm					
Diode Array Detector	190 – 380 nm			Bunchwidth 1		
Run Time	10 minutes					
Wash Solvent	50:50 water:methanol					

Preparation of Stock Standard Solution:

Weigh accurately 0.095 - 0.105 g of Morphine Sulfate reference standard into a 100 mL volumetric flask and dissolve in water. Dilute to volume with water and mix well.

Preparation of Calibration Standard Solution:

Pipette 5.0mL of stock standard solution into a 50 mL volumetric flask and dilute to volume with water.

To be prepared in duplicate to provide a recovery standard.

Preparation of a Test Sample Solution:

Pipette 1.0 mL of well mixed sample into a 100 mL volumetric flask and dissolve in water. Dilute to volume with water and mix well.

Preparation of a Limit Stock Solution:

Pipette 5.0 mL of Calibration Standard Solution into a 100 mL volumetric flask and dilute to volume with water (5%)

Preparation of 0.05% Limit Test Solution:

Pipette 1.0mL of Limit Stock Solution into a 100 mL volumetric flask and dilute to volume with water.

Preparation of a System Suitability Solution:

Pipette 5.0 mL of stock standard solution into a 50 mL volumetric flask and add 2.0 mL of 10 volume peroxide. Dilute to volume with water and mix well. Fill a HPLC vial with the solution and heat for 30 minutes at 80°C. When cooled inject this solution.

Analytical Solution Stability

Standard solutions are stable for 42 days when stored at ambient temperature.

Calculation of Amounts

Morphine sulfate and related substances are quantified by external standard and single point calibration. Related substances are quantified relative to Morphine sulfate with the use of relative response factors.

$$\text{Corrected Std Weight} = \frac{\text{weight taken (g)} \times \text{purity of standard}}{100}$$

$$\text{Morphine sulfate (\% w/v)} = \frac{\text{Corrected std weight} \times \text{Area Morphine sulfate in spl} \times 100 \times 100}{\text{Area Morphine Sulfate in std} \times 1}$$

$$\text{Rel Subs (\% w/v)} = \frac{\text{Corrected std weight} \times \text{Area Rel Subs in spl} \times 100 \times 100 \times \text{Factor}}{\text{Area Morphine Sulfate in std} \times 1}$$

Results are calculated in %w/v, they can be converted to mg/mL using the following equation:

$$\text{Result (mg/mL)} = \frac{\text{Result (\%w/v)} \times 100}{1000}$$

Expected retention times:

Component	Retention time window/ Relative Retention Time (RRT)	Relative Response Factor
Morphine sulfate	4.1- 4.5 minutes RRT 1.0	1.0
Impurity A (codeine)	7.4 – 8.0 minutes RRT 1.8	1.0
Impurity B (pseudomorphine)	3.2 – 3.5 minutes RRT 0.8	0.5
Impurity C	6.7 – 7.2 minutes RRT 1.6	0.4
Impurity E	4.4 – 4.7 minutes RRT 1.1	0.5
Impurity F	5.0 – 5.5 minutes RRT 1.2	1.0

Example chromatograms:




Figure P.5.2.1 – Chromatogram of a typical injection of calibration standard solution




Figure P.5.2.2 – Chromatogram of a typical injection of test sample solution




Figure P.5.2.3 – Chromatogram of an injection of morphine sulfate spiked with known impurities (baseline zoomed)




Figure P.5.2.4 – Chromatogram of an injection of the system suitability solution demonstrating resolution between morphine sulfate and Impurity B (pseudomorphine)

P.5.3 Validation of Analytical Procedures

The validation of analytical procedures is not required as they are taken from the European Pharmacopoeia and British Pharmacopoeia, if not stated otherwise below.

Assay of Morphine sulfate and known/unknown related substances by HPLC-UV

Parameter/Assessment	Acceptance criteria	Result
Specificity	<ul style="list-style-type: none"> • The peak due Morphine sulfate must be free from interference • The minimum resolution between Morphine sulfate and any other peak must be >1.5. • Peak purity of Morphine sulfate in all unadulterated samples should be between 98.0 – 102.0 % of the standard. • The UV spectra of Morphine sulfate must be concurrent between sample and standard. 	Specificity confirmed
Linearity (Samples of Morphine sulfate at 0.05-120%)	Correlation Co-efficient $R^2 >99.9\%$	$R^2 = 100.00$
Accuracy (spiked samples 0.05, 0.1, 1.0, 80, 100 and 120%; 6 repeats)	Recovered amounts should be as below: At 0.05%, within 70.0 – 130.0% 0.1%, within 80.0 – 120.0% At 1.0% within 90.0 – 110.0% At 80,100, 120% - within 98.0-102.0%	Accuracy confirmed for Morphine sulfate
Precision (repeatability) c) 6 replicates tested in duplicate, d) 10 repeats of same sample	c) %RSD ≤ 2.0 d) %RSD ≤ 1.0	c) 0.4%RSD d) 0.3%RSD
Limit of Detection of Morphine sulfate	S:N of approx. 10	0.025%, S:N 5.8
Limit of Quantification of Morphine sulfate	S:N of approx. 3	0.05%, S:N 10.5

Intermediate precision is not performed at this stage of the application.

P.5.3.1 Validation of the Test for Bioburden

Not required at this stage of the application

P.5.3.2 Validation of the Test for Sterility

The validation report has been included as Attachment 7.

P.5.3.3 Validation of the Test for Bacterial Endotoxins

The validation report has been included as Attachment 8.

P.5.4 Batch Analysis

The below batch is representative of a batch intended for use in the proposed clinical trial.

Test	Batch number	200217X
	Date of Manufacture	17Feb2020
	Batch size	2.5L (710 units sub batch)
	Acceptance Criteria	Result
Examination	A clear, colourless to pale yellow solution free from particulate contamination	Complies
pH	2.5 – 6.5	4.6
Identification of Morphine sulfate	1. Retention time comparison with a reference standard	Complies
	2. UV Spectral Comparison with a reference standard	Complies
Assay of Morphine sulfate	9.5 – 10.5mg/mL	10.1mg/mL
Codeine (Impurity A)	Not greater than 0.5% wrt API	0.05% wrt API
Any other single Known Related Substance	Not greater than 0.2% wrt API	Complies
Any other single Unknown Related Substance	Not greater than 0.2% wrt API	Complies
Total Known/Unknown Related Substances (% wrt API)	Not greater than 2.0% wrt API	Complies

Sterility Test	Pass	Pass
BET	<17.0 EU/mg	TBC
Sub-visible particle count	10µm ≤6000/container 25µm ≤600/container	28.5 0.7

P.7 Container Closure System

Primary Packaging

2ml Type 1 Fiolax clear Form D glass ampoules according to Ph. Eur. 3.2.1.

P.8 Stability

Storage Conditions:

Store in a dry place. Protect from light.

Shelf-life:

Based on historical data of existing morphine products an initial 12 months expiry is set for morphine 10mg/mL in 2mL glass ampoules containing 1mL with a rolling program to extend the shelf-life to 18 months (for subsequent batches) from data available via an ongoing stability study plan (see 'Shelf-life Extension Program' below).

The preparation is to be used immediately after opening so no in-use stability data will be presented.

Samples from one batch of ampoules will be included in a supporting ongoing stability study program with analysis performed as described below. Data from this study will be reviewed at each time point to verify the predicted shelf life set at 18 months.

Stability control

The stability study protocol has been designed to provide assurance of ongoing stability:

Product Code	MOR19S	Batch number	200217X	DOM	17 Feb 2020
Product Name	Morphine sulphate injection				
Strength	10mg/mL	Pack size	1mL in 2mL ampoule		
Aim of Study					
Development batch to perform stability study in support of Packman clinical Trial C013					
Duration of Stability Study	18M				
Timepoints required	0,1,2,3,6,9,12,14,18M				
Storage Condition(s)	25°C/60%RH, 30°C/60%RH, 40°C/75%RH				

Testing Requirements:

Test	Description
(a)	Examination
(b)	pH
(c)	Assay and Related Substances
(d)	Sterility
(e)	Particle Counts
(f)	Bacterial Endotoxins

Timepoints No. of samples required (tests in brackets)

	T=0	1M	2M	3M	6M	9M	12M	14M	18M
5°C	97 (a – f)								
25°C				12 (a–c)	12 (a–c)	12 (a–c)	12 (a–c)	12 (a–c)	82 (a–e)
30°C				12 (a–c)	12 (a–c)	12 (a–c)	12 (a–c)		
40°C		12 (a–c)	12 (a–c)	12 (a–c)	12 (a–c)				

Shelf-life Extension Program

The initial 12 months stability may be extended during the Clinical Trial based on the results of the stability study performed on a test batch. In the extension, extrapolation will be used requiring real-time data of ketamine assay and degradation products before an expiry is set as follows:

Real-time stability data available	Proposed shelf-life
3 months accelerated (40°C/75%RH)	12 months
14 months at ambient	14 months
18 months at ambient	18 months

The specification used will be the same as the Release analysis. Shelf-life will not be extended if the trend analysis performed according to ICH Q1E shows that the specification at the end of shelf-life is not met.

Stability results available at the time of submission are included in Attachment 9.

2.1.A Appendices

2.1.A.1 Facilities and Equipment

Role: Development and manufacture of ampoules, clinicals trials labelling, packaging, final QP release and storage/distribution

Calderdale and Huddersfield NHS Foundation Trust trading as Huddersfield Pharmacy Specials (HPS)

Manufacturing site: Acre Mills, Gate 2, School Street West, Lindley, Huddersfield, HD3 3ET, UK

MIA(IMP) Authorisation: MIA(IMP) 19055

2.1.A.2 Adventitious Agents Safety Evaluation

All materials used in the manufacture are assessed for compliance against TSE/BSE regulations during the supplier assessment by the respective manufacturers. The following TSE-free statements have been included as attachments to this dossier:

- Attachment 4: TSE-free statement for sodium chloride
- Attachment 10: TSE-free statement for disodium edetate
- Attachment 11: TSE-free statement for ketamine hydrochloride
- Attachment 12: TSE-free statement for morphine sulphate

2.1.A.3 Novel excipients

Not applicable.

2.1.A.4 Solvents for Reconstitution and Diluents

Not applicable.

2.1.A.5 Labelling

Secondary packaging label: Packs

PACKMaN

Pack Number: *pre-printed number as per randomisation list*

3 x 1mL ampoules containing either:
Ketamine 15mg/ml solution for injection or
Morphine 10mg/ml solution for injection

Directions for use: To be administered via the intravenous or intraosseous route as directed in the clinical trial protocol.

Storage Conditions: Store in a dry place. Protect from light.

Batch number: *pre-printed information assigned at manufacture*

Expiry Date: *dd/mmm/yyyy (assigned at manufacture)*

For emergency unblinding contact the regional ambulance control centre:

Yorkshire Ambulance Service: [TBC](#).

West Midlands Ambulance Service: [TBC](#).

Contact: Dr Michael Smyth, The University of Warwick, Gibbet Hill Road,
Coventry, CV4 7AL. Telephone: 02476 150478 (Warwick Clinical Trials Unit).

FOR CLINICAL TRIAL USE ONLY

EudraCT No.: 2020-000154-10

Notes:

- Labels will be white with black text

Primary packaging label: ketamine and morphine ampoules

PACKMaN

Pack No.: *pre-printed*

Ketamine 15mg/mL or Morphine 10mg/mL
intravenous or intraosseous injection

BN: *pre-printed information assigned at manufacture*

The University of Warwick

Notes:

- Labels will be white with black text

Rear of all IMP packs:

Inclusion criteria	Exclusion criteria
<ul style="list-style-type: none">• Age ≥ 16• Patient reports a pain score $\geq 7/10$ on a 0-10 NRS following acute traumatic injury• Intravenous or intraosseous access obtained• Determined by a paramedic to require IV morphine or equivalent	<ul style="list-style-type: none">• Known or suspected pregnancy• Unable to articulate severity of pain using the 0-10 NRS• Lack of capacity due to a reason other than pain• Ketamine or opioid analgesia prior to randomisation• Contraindication to either ketamine or morphine as per the SmPC• Patient declines participation• Known prisoner

2.1.A.6 Attachments

Attachment 1: MIA(IMP) for Calderdale and Huddersfield NHS Foundation Trust trading as Huddersfield Pharmacy Specials (HPS)

Attachment 2: Certificate of Suitability for ketamine hydrochloride

Attachment 3: Certificate of Suitability for morphine sulfate

Attachment 4: TSE-free statement for sodium chloride

Attachment 5: Sterility testing method validation report for ketamine hydrochloride injection 15mg in 1ml

Attachment 6: LAL validation report for ketamine hydrochloride injection 15mg in 1ml

Attachment 7: Sterility testing method validation report for morphine sulfate injection 10mg in 1ml

Attachment 8: LAL validation report for morphine sulfate injection 10mg in 1ml

Attachment 9: IMP stability test protocols and results

Attachment 10: TSE-free statement for disodium edetate

Attachment 11: TSE-free statement for ketamine hydrochloride

Attachment 12: TSE-free statement for morphine sulphate

Version Control

Version	Date	Comments
1.0	29 July 2020	New document.
1.1	16 Oct 2020	<p>P.8 Stability (for both products):</p> <ul style="list-style-type: none">- Storage conditions amended to remove the 25°C restriction. <p>2.1.A.5 Labelling:</p> <ul style="list-style-type: none">- IO route of administration added to primary and secondary labels- Main contact details amended on the secondary label- Storage conditions amended on the secondary label- Emergency unblinding details amended on the secondary label- Label for rear of all packs: inclusion and exclusion criteria added <p>Attachments:</p> <ul style="list-style-type: none">- Attachment 9: Stability results updated to include T6.



Medicines & Healthcare products
Regulatory Agency



MIA(IMP) MIA(IMP) 19055
NUMBER:

Version: 18

MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY
On behalf of the Licensing Authority under:
The Human Medicines Regulations 2012 (SI 2012/1916)

Manufacturer's Authorisation - Investigational Medicinal Products

SECTION 1A

1. Authorisation Number

MIA(IMP) Number: MIA(IMP) 19055

2. Name of Authorisation Holder

CALDERDALE AND HUDDERSFIELD NHS FOUNDATION TRUST

3. Trading Style

HUDDERSFIELD PHARMACY SPECIALS (HPS)

4. Address(es) of manufacturing/importing site(s)

(All authorised sites should be listed if not covered by separate licences)

MHRA SITE NUMBER:	SITE NAME:	ADDRESS:
431097	CALDERDALE AND HUDDERSFIELD NHS FOUNDATION TRUST	GATE 2 ACRE MILL, SCHOOL STREET WEST, HUDDERSFIELD, HD3 3ET, UNITED KINGDOM

5. Legally registered address of Authorisation Holder

GATE 2 ACRE MILL, SCHOOL STREET WEST, HUDDERSFIELD, HD3 3ET, UNITED KINGDOM

6. Scope of authorisation and dosage forms

See Annex 2

7. Legal basis of authorisation

See Section 1B of authorisation.



Medicines & Healthcare products
Regulatory Agency



MIA(IMP) MIA(IMP) 19055
NUMBER:

Version: 18

8. Name of responsible officer of the competent authority of the member state granting the manufacturing authorisation

Olumuyiwa Abimbola

SECTION 1A (continued)

9. Date 24/06/2020

10. Annexes attached

Annex 2

Optional Annexes

Annex 4 (Contract Laboratories)

Annex 5 (Name of Qualified Person)

Annex 6 (Name of Responsible Person)

Annex 8 (Manufactured/Imported products)

Annex 9 (Storage Sites)



Medicines & Healthcare products
Regulatory Agency



MIA(IMP) MIA(IMP) 19055
NUMBER:

Version: 18

MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY
On behalf of the Licensing Authority under:
The Human Medicines Regulations 2012 (SI 2012/1916)

Manufacturer's Authorisation - Investigational Medicinal Products

SECTION 1B

1. This authorisation is granted in accordance with the provisions of the Medicines for Human Use (Clinical Trials) Regulations 2004 as amended [S.I. 2004/1031] which implement Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001.
2. It permits the authorisation holder named on page 1 of Section 1 of the authorisation to manufacture, assemble and/or import investigational medicinal products for human use in accordance with Regulation 41 of the Medicines for Human Use (Clinical Trials) Regulations 2004 as amended [S.I. 2004/1031] (as detailed in section 3 of this authorisation) and is subject to the provisions identified on page 2 of Section 1 of this authorisation.
3. In this document a Manufacturers Authorisation for Investigational Medicinal Products may be referred to as MIA(IMP) and the Medicines and Healthcare products Regulatory Agency (acting on behalf of the Licensing Authority as defined in Regulation 6 of The Human Medicines Regulations 2012 (SI 2012/1916) may be referred to as MHRA.
4. The authorisation holder must inform the MHRA, in advance, of any change to the details submitted by him and/or included in this authorisation. All changes must be approved by the MHRA to have effect. If the business should change hands, the company or person taking over the business will have to obtain a new authorisation before commencing the manufacture, assembly or importation of investigational medicinal products.

Attention is drawn to the structure of this authorisation (as detailed on page 4 of Section 1) and to its completeness in accordance with that structure. This is of particular relevance where the holder of the authorisation is using it as evidence to a third party in support of claims to carry out those operations and activities to which this authorisation applies on premises and using personnel covered by this authorisation.



Medicines & Healthcare products
Regulatory Agency



MIA(IMP) MIA(IMP) 19055
NUMBER:

Version: 18

SECTION 1B (continued)

5. Authorisation Structure

This authorisation is divided into three sections.

- (a) Section 1 (this section) identifies the authorisation holder and the responsible officer for the issue of the authorisation. This section would not usually be replaced during routine variations of the authorisation unless the authorisation holder details are varied.
 - (b) Section 2 lists variations to the authorisation. A replacement section 2 will be issued each time the authorisation is varied.
 - (c) Section 3 contains the details relating to each site named on the authorisation. Where there is more than one site there will be more than one part to Section 3. When a variation is made to the details of a site named in Section 3 the relevant part of Section 3 will be replaced.
 - (d) The authorisation holder is required to attach to his authorisation any replacement pages issued by MHRA and to mark or destroy superseded pages as to render them invalid.
-

6. Provisions

- a) The provisions of Schedule 7 of the Medicines for Human Use (Clinical Trials) Regulations 2004 as amended [S.I. 2004/1031] shall apply to the authorisation. For manufacture and/or assembly Parts 1 and 2 of Schedule 7 apply and for importation Parts 1 and 3 of Schedule 7 apply in accordance with Regulation 40(4) of the Medicines for Human Use (Clinical Trials) Regulations 2004 as amended [S.I. 2004/1031] subject to Regulation 38(2).



Medicines & Healthcare products
Regulatory Agency



MIA(IMP) MIA(IMP) 19055
NUMBER:

Version: 18

MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY

On behalf of the Licensing Authority under:
The Human Medicines Regulations 2012 (SI 2012/1916)

Manufacturer's Authorisation - Investigational Medicinal Products

SECTION 2

VARIATION HISTORY

This page will be amended if the licence is varied.

Date	Variation Detail
12/12/2005	Initial application
25/10/2006	Add two Qualified Persons Ms J L New and Mr J M Allen
21/02/2007	Internal Variation to amend errors on licence.
10/06/2008	Variation to add an additional site at Acre Mills and eight contract laboratories.
11/07/2008	Internal variation to correct errors.
23/09/2008	Variation to (1) Remove Mr John Harwood from Licence (2) Add Mr Don Wallace as LH contact (3) Add Mr Don Wallace as PM (4) Replace Mr Don Wallace with Mr J M Allen as QC (5) Add Mr Don Wallace as SC on sites 431097 & 11706. (6) Changes effective 08/09/2008.
26/10/2008	Update licence to EUDRA GMP format.
28/08/2009	Variation to remove Mr D Wallace as LH contact, QP and PM for sites: 431097 & 11706, and replace with Dr S.A.Langford. Remove Mr M Allen as QC and replace with Dr N.C. Crab. Remove site 20407 as requested by M.I.
23/07/2010	Variation: 1.Delete site 11706. 2. Site 431097 Remove Dr N Crabb as QC and replace him with Mr A Myers and update site activities.
08/10/2010	Variation to add site: 11706
05/07/2011	Variation to edit site 431097
03/06/2013	Variation to remove site 11706.
22/08/2013	Variation:1. Site 431097 delete Other Biologicals and Pressurised preparations.
30/08/2013	Internal variation to correct errors
29/10/2015	Variation: Add Ms Jodi New as PM (Site 431097)
21/11/2016	Variation: to add Roger Brookes as Head of Production and to remove Jodi New and Stephen Langford. Site no 431097



Medicines & Healthcare products
Regulatory Agency



MIA(IMP) MIA(IMP) 19055
NUMBER:

Version: 18

13/05/2019	Variation to add Primary packing activities. Change of trading style. Remove sites 4571, 9776. Add sites 16988769 and 92250 as contract laboratories
24/06/2020	Variation to: -Add Export to site 431097. -Add contract lab site 336740.



Medicines & Healthcare products
Regulatory Agency



MIA(IMP) MIA(IMP)
NUMBER: 19055

MHRA Site No: 431097

VERSION: 18

MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY

On behalf of the Licensing Authority under:
The Human Medicines Regulations 2012 (SI 2012/1916)

Manufacturer's Authorisation - Investigational Medicinal Products

SECTION 3

ANNEX 2 - SITE INFORMATION

SCOPE OF AUTHORISATION

Name and address of site:

SITE NAME:	CALDERDALE AND HUDDERSFIELD NHS FOUNDATION TRUST
ADDRESS:	GATE 2 ACRE MILL, SCHOOL STREET WEST, HUDDERSFIELD, HD3 3ET, UNITED KINGDOM
MHRA SITE NUMBER:	431097

Type of products handled

Human Investigational Medicinal Products for phase I, II, III clinical trials (optional)

Authorised operations

Manufacturing Operations of Investigational Medicinal Products (according to Part 1)	Authorised
Importation of Investigational Medicinal Products (according to Part 2)	Not Authorised



Medicines & Healthcare products
Regulatory Agency



MIA(IMP) MIA(IMP)
NUMBER: 19055

MHRA Site No: 431097

VERSION: 18

ANNEX 2 – SITE INFORMATION (continued)

Part 1 – MANUFACTURING OPERATIONS OF INVESTIGATIONAL MEDICINAL PRODUCTS

- authorised manufacturing operations include total and partial manufacturing (including various processes of dividing up, packaging or presentation), batch release and certification, importation, storage and distribution of specified dosage forms unless informed to the contrary;
- quality control testing and/or release and batch certification activities without manufacturing operations should be specified under the relevant items;
- if the company is engaged in manufacture of products with special requirements e.g. radiopharmaceuticals or products containing penicillin, sulphonamides, cytotoxics, cephalosporins, substances with hormonal activity or other or potentially hazardous active ingredients this should be stated under the relevant product type and dosage form (applicable to all sections of Part 1 apart from sections 1.5.2 and 1.6)

1.1	Sterile Investigational Medicinal Products	Manufacture
1.1.1	Aseptically prepared (processing operations for the following dosage forms)	
	1.1.1.1 Large volume liquids	Authorised
	1.1.1.2 Lyophilisates	Not Authorised
	1.1.1.3 Semi-solids	Authorised
	1.1.1.4 Small volume liquids	Authorised
	1.1.1.5 Solids and implants	Not Authorised
	1.1.1.6 Other aseptically prepared products	Not Authorised



Medicines & Healthcare products
Regulatory Agency



MIA(IMP) NUMBER: MIA(IMP) 19055

MHRA Site No: 431097

VERSION: 18

1.1.2	<i>Terminally Sterilised (processing operations for the following dosage forms)</i>	Manufacture
	1.1.2.1 Large volume liquids	Authorised
	1.1.2.2 Semi-solids	Authorised
	1.1.2.3 Small volume liquids	Authorised
	1.1.2.4 Solids and implants	Not Authorised
	1.1.2.5 Other terminally sterilised prepared products	Not Authorised
1.1.3	<i>Batch certification</i>	Authorised



Medicines & Healthcare products
Regulatory Agency



MIA(IMP)
NUMBER:

MIA(IMP)
19055

MHRA Site No: 431097

VERSION: 18

1.2	Non-sterile investigational medicinal products	Manufacture
1.2.1	Non-Sterile Products (processing operations for the following dosage forms)	
	1.2.1.1 Capsules, hard shell	Authorised
	1.2.1.2 Capsules, soft shell	Not Authorised
	1.2.1.3 Chewing gums	Not Authorised
	1.2.1.4 Impregnated matrices	Not Authorised
	1.2.1.5 Liquids for external use	Authorised
	1.2.1.6 Liquids for internal use	Authorised
	1.2.1.7 Medicinal gases	Not Authorised
	1.2.1.8 Other solid dosage forms Special Requirements: Other Over encapsulation	Authorised
	1.2.1.9 Pressurised preparations	Not Authorised
	1.2.1.10 Radionuclide generators	Not Authorised
	1.2.1.11 Semi-solids	Authorised
	1.2.1.12 Suppositories	Authorised
	1.2.1.13 Tablets	Not Authorised



Medicines & Healthcare products
Regulatory Agency



MIA(IMP)
NUMBER:

MIA(IMP)
19055

MHRA Site No: 431097

VERSION: 18

	1.2.1.14 Transdermal patches	Not Authorised
	1.2.1.15 Other non-sterile medicinal products	Not Authorised
1.2.2	Batch certification	Authorised



Medicines & Healthcare products
Regulatory Agency



MIA(IMP) NUMBER: MIA(IMP) 19055

MHRA Site No: 431097

VERSION: 18

1.3	Biological investigational medicinal products	Manufacture
1.3.1	Biological medicinal products (list of product types)	
	1.3.1.1 Blood products	Not Authorised
	1.3.1.2 Immunological products	Not Authorised
	1.3.1.3 Cell therapy products	Not Authorised
	1.3.1.4 Gene therapy products	Not Authorised
	1.3.1.5 Biotechnology products	Not Authorised
	1.3.1.6 Human or animal extracted products	Not Authorised
	1.3.1.7 Tissue Engineered Products	Not Authorised
	1.3.1.8 Other biological medicinal products	Not Authorised
1.3.2	Batch certification	
	1.3.2.1 Blood products	Not Authorised
	1.3.2.2 Immunological products	Not Authorised
	1.3.2.3 Cell therapy products	Not Authorised
	1.3.2.4 Gene therapy products	Not Authorised



Medicines & Healthcare products
Regulatory Agency



MIA(IMP)
NUMBER:

MIA(IMP)
19055

MHRA Site No: 431097

VERSION: 18

	1.3.2.5 Biotechnology products	Not Authorised
	1.3.2.6 Human or animal extracted products	Not Authorised
	1.3.2.7 Tissue Engineered Products	Not Authorised
	1.3.2.8 Other biological medicinal products	Not Authorised



Medicines & Healthcare products
Regulatory Agency



MIA(IMP) MIA(IMP)
NUMBER: 19055

MHRA Site No: 431097

VERSION: 18

1.4	<i>Other investigational medicinal products or manufacturing activity</i> (any other relevant manufacturing activity/product type that is not covered above e.g. sterilisation of active substances, manufacture of biological active starting materials (when required by national legislation), medicinal gases, herbal or homeopathic products, bulk or total manufacturing, etc).	Manufacture
1.4.1	Manufacture of:	
	1.4.1.1 Herbal products	Not Authorised
	1.4.1.2 Homoeopathic products	Not Authorised
	1.4.1.3 Other Heparin and insulin	Authorised
1.4.2	Sterilisation of active substances/excipients/finished products:	
	1.4.2.1 Filtration	Authorised
	1.4.2.2 Dry heat	Authorised
	1.4.2.3 Moist heat	Authorised
	1.4.2.4 Chemical	Not Authorised
	1.4.2.5 Gamma irradiation	Not Authorised
	1.4.2.6 Electron beam	Not Authorised
1.4.3	Others	Not Authorised



Medicines & Healthcare products
Regulatory Agency



MIA(IMP)
NUMBER:

MIA(IMP)
19055

MHRA Site No: 431097

VERSION: 18

1.5	Packaging	Packaging
1.5.1	Primary packing	
	1.5.1.1 Capsules, hard shell	Not Authorised
	1.5.1.2 Capsules, soft shell	Not Authorised
	1.5.1.3 Chewing gums	Not Authorised
	1.5.1.4 Impregnated matrices	Not Authorised
	1.5.1.5 Liquids for external use	Authorised
	1.5.1.6 Liquids for internal use	Authorised
	1.5.1.7 Medicinal gases	Not Authorised
	1.5.1.8 Other solid dosage forms	Not Authorised
	1.5.1.9 Pressurised preparations	Not Authorised
	1.5.1.10 Radionuclide generators	Not Authorised
	1.5.1.11 Semi-solids	Authorised
	1.5.1.12 Suppositories	Authorised
	1.5.1.13 Tablets	Authorised



Medicines & Healthcare products
Regulatory Agency



MIA(IMP)
NUMBER:

MIA(IMP)
19055

MHRA Site No: 431097

VERSION: 18

	1.5.1.14 Transdermal patches	Not Authorised
	1.5.1.15 Other non-sterile medicinal products	Not Authorised
1.5.2	Secondary packing	Authorised



Medicines & Healthcare products
Regulatory Agency



MIA(IMP) MIA(IMP)
NUMBER: 19055

MHRA Site No: 431097

VERSION: 18

1.6	Quality control testing	
	1.6.1 Microbiological: sterility	Authorised
	1.6.2 Microbiological: non-sterility	Authorised
	1.6.3 Chemical/Physical	Authorised
	1.6.4 Biological	Not Authorised

Any restrictions or clarifying remarks related to the scope of these Manufacturing operations:



Medicines & Healthcare products
Regulatory Agency



MIA(IMP) NUMBER: MIA(IMP) 19055

MHRA Site No: 431097

VERSION: 18

ANNEX 5/6 – SITE INFORMATION (continued)

Personnel

<u>Person Number</u>	<u>Name</u>	<u>Personnel Type</u>			
		<u>QP</u>	<u>TQP</u>	<u>PM</u>	<u>QC</u>
13897503	Mr Roger Brookes	No	No	Yes	No
2342688	Mr Andrew Myers	No	No	No	Yes
625285	Mr J M Allen	No	Yes	No	No

Key to Roles:

- QP – Qualified Person
- TQP – Transitional Qualified Person
- PM – Production Manager/Supervisor
- QC – Person responsible for Quality Control



Medicines & Healthcare products
Regulatory Agency



MIA(IMP)
NUMBER:

MIA(IMP) 19055

VERSION: 18

ANNEX 4 – CONTRACT LABORATORIES

MHRA SITE NUMBER:	LABORATORY NAME:	ADDRESS:
5566	QUALITY CONTROL NORTH WEST	STEPPING HILL HOSPITAL, STOCKPORT, SK2 7JE, UNITED KINGDOM
30429	HONEYMAN LIMITED	HARMIRE ENTERPRISE PARK, BARNARD CASTLE, DL12 8BN, UNITED KINGDOM
91520	PHARMACEUTICAL CHEMISTRY AND MICROBIOLOGY LAB (LIVERPOOL)	PHARMACY PRACTICE UNIT, 70 PEMBROKE PLACE, LIVERPOOL, L69 3GF, UNITED KINGDOM
92250	ALS LABORATORIES (UK) LIMITED	2 BARTHOLOMEW'S WALK, CAMBRIDGESHIRE BUSINESS PARK, ELY, CB7 4ZE, UNITED KINGDOM
93666	JC ANALYTICAL LIMITED	FLORENCE ROAD INDUSTRIAL ESTATE, KELLY BRAY, CALLINGTON, PL17 8EX, UNITED KINGDOM
318192	STOCKTON QUALITY CONTROL LABORATORY	UNIVERSITY HOSPITAL OF NORTH TEES, HARDWICK ROAD, STOCKTON-ON-TEES, TS19 8PE, UNITED KINGDOM
336740	MELBOURN SCIENTIFIC LIMITED TA INTERTEK MELBOURN	SAXON WAY, MELBOURN, ROYSTON, SG8 6DN, UNITED KINGDOM
16988769	NORTHUMBRIA PHARMA	NETPARK, THOMAS WRIGHT WAY, SEDGEFIELD, STOCKTON-ON-TEES, TS21 3FD, UNITED KINGDOM



Medicines & Healthcare products
Regulatory Agency



MIA(IMP)
NUMBER:

MIA(IMP) 19055

VERSION: 18

ANNEX 9 – STORAGE SITES

MHRA SITE NUMBER:	SITE NAME:	ADDRESS:
431097	CALDERDALE AND HUDDERSFIELD NHS FOUNDATION TRUST	GATE 2 ACRE MILL, SCHOOL STREET WEST, HUDDERSFIELD, HD3 3ET, UNITED KINGDOM

European Directorate for the
Quality of Medicines & HealthCareCOUNCIL OF EUROPE
CONSEIL DE L'EUROPE**Certification of Substances Division****Certificate of suitability
No. R1-CEP 2005-281-Rev 00**

1 *Name of the substance:*
2 **KETAMINE HYDROCHLORIDE**

3 *Name of holder:*
4 **CU CHEMIE UETIKON GMBH**
5 Raiffeisenstrasse 4
6 Germany-77933 Lahr

7 *Site(s) of production:*
8 **CU CHEMIE UETIKON GMBH**
9 Raiffeisenstrasse 4
10 Germany-77933 Lahr

11 **THIS CERTIFICATE SUPERSEDES THE PREVIOUS CERTIFICATE**
12 **R0-CEP 2005-281-REV 01**

13 After examination of the information provided on the manufacturing method and subsequent
14 processes (including purification) for this substance on the site(s) of production mentioned
15 above, we certify that the quality of the substance is suitably controlled by the current version
16 of the monograph **Ketamine hydrochloride** no. 1020 of the European Pharmacopoeia,
17 current edition including supplements.

18 In the last steps of the synthesis acetone and ethyl acetate are used as solvents. Their
19 residual content is limited by the test for loss on drying described in the monograph, with a
20 limit of not more than 0.5%.

21 The substance is packed in double polyethylene bags placed in a polyethylene drum.

22 The holder of the certificate has declared the absence of use of material of human or animal
23 origin in the manufacture of the substance.

24 The submitted dossier must be updated after any significant change that may alter the quality,
25 safety or efficacy of the substance.

26 Manufacture of the substance shall take place in accordance with the Good Manufacturing
27 Practice and in accordance with the dossier submitted.

Address: 7, allée Kastner, CS 30026

F - 67081 Strasbourg (France)

Telephone: 33 (0) 3 88 41 30 30 - Fax: 33 (0) 3 88 41 27 71 - e-mail: cep@edqm.eu

Internet : <http://www.edqm.eu>

Certification of Substances Department

**Certificate of suitability
No. R1-CEP 2001-239-Rev 06**

1 *Name of the substance:*

2 **MORPHINE SULFATE**

3 *Name of holder:*

4 **MACFARLAN SMITH LIMITED**

5 10 Wheatfield Road

6 United Kingdom-EH11 2QA Edinburgh, Scotland

7 *Site(s) of production:*

8 **SEE ANNEX 1**

9 **THIS CERTIFICATE SUPERSEDES THE PREVIOUS CERTIFICATE**
10 **R1-CEP 2001-239-REV 05**

11 After examination of the information provided on the manufacturing method and subsequent
12 processes (including purification) for this substance on the site(s) of production listed in annex, we
13 certify that the quality of the substance is suitably controlled by the current version of the
14 monograph **MORPHINE SULFATE** no. 1244 of the European Pharmacopoeia, current edition
15 including supplements, only if it is supplemented by the test(s) mentioned below, based on the
16 analytical procedure(s) given in annex.

17 Any unspecified impurity detected by the test for related substances of the monograph is
18 limited to not more than 0.10%.

19 – Test for residual solvents by gas chromatography (Annex 2)
20 Ethanol not more than 5000 ppm
21 Methanol not more than 3000 ppm

22 The re-test period of the substance is 5 years if stored in a polyethylene bag placed in either a
23 polyethylene, aluminium or polypropylene container.

24 The holder of the certificate has declared the absence of use of material of human or animal
25 origin in the manufacture of the substance.

26 The submitted dossier must be updated after any significant change that may alter the quality,
27 safety or efficacy of the substance.

28 Manufacture of the substance shall take place in accordance with the Good Manufacturing Practice
29 and in accordance with the dossier submitted.

Address: 7 Allée Kastner, CS 30026
F-67081 Strasbourg (France)

Tel: +33 (0) 3 88 41 30 30 – Fax: +33 (0) 3 88 41 27 71 - e-mail: cep@edqm.eu

Internet: <http://www.edqm.eu>

30 Failure to comply with these provisions will render this certificate void.

31 This certificate is renewed from **29 July 2007** according to the provisions of Resolution AP-CSP
32 (07) 1, and of Directive 2001/83/EC and Directive 2001/82/EC and any subsequent amendment,
33 and the related guidelines.

34 This certificate has two annexes, the first of 1 page and the second of 2 pages.

35 This certificate has:
36 lines:

On behalf of the
Director of EDQM



Strasbourg, 27 February 2017

DECLARATION OF ACCESS *(to be filled in by the certificate holder under their own responsibility)*

MACFARLAN SMITH LIMITED, as holder of the certificate of suitability

R1-CEP 2001-239-Rev 06 for Morphine sulfate

hereby authorises Huddersfield Pharmacy Specials
(name of the pharmaceutical company)

to use the above-mentioned certificate of suitability in support of their application(s) for the following
Marketing Authorisation(s): *(name of product(s) and marketing number(s), if known)*

For information only

The holder also certifies that no significant changes to the operations as described in the CEP dossier
have been made since the granting of this version of the certificate.

Date and Signature *(of the CEP holder)*:

S C 17 MARCH 2020

Address: 7 Allée Kastner, CS 30026
F-67081 Strasbourg (France)

Tel: +33 (0) 3 88 41 30 30 – Fax: +33 (0) 3 88 41 27 71 - e-mail: cep@edqm.eu

Internet: <http://www.edqm.eu>

Certification of Substances Department

Annex 1: Site(s) of production for R1-CEP 2001-239-Rev 06

Production of Morphine sulfate:

MACFARLAN SMITH LIMITED

10 Wheatfield Road

United Kingdom-EH11 2QA Edinburgh, Scotland

Residual Solvents

Internal Standard Stock Solution

Pipette 0.2ml of n-propanol into a 100ml volumetric flask and dilute to volume with purified water.

Calibration Stock Solution

Pipette 1ml of methanol, 1ml of ethanol, 1ml of acetone and 1ml of isopropanol into a 500ml volumetric flask containing about 450ml of purified water. Shake vigorously to dissolve. Dilute to volume with purified water.

Level 1 Calibration Solution

Pipette 20ml of Calibration Stock Solution and 20ml of Internal Standard Stock Solution into a 2000ml volumetric flask and dilute to volume with purified water. Transfer 10ml aliquots into suitable vials and crimp seal.

Level 2 Calibration Solution

Pipette 100ml of Calibration Stock Solution and 20ml of Internal Standard Stock Solution into a 2000ml volumetric flask and dilute to volume with purified water. Transfer 10ml aliquots into suitable vials and crimp seal.

Sample Internal Standard Solution

Pipette 20ml of Internal Standard Stock Solution into a 2000ml volumetric flask and dilute to volume with purified water.

Test Solution

Weigh accurately about 1g of sample into a suitable vial. Add 10ml of sample Internal Standard Solution and crimp seal. Ensure that the sample is dissolved before continuing. Prepare 2 such vials for each sample.

Headspace Autosampler Conditions

Sample temperature	:	70°C
Needle temperature	:	100°C
Transfer temperature	:	180°C
GC cycle time	:	15 minutes
Thermostatting time	:	15 minutes
Pressurisation time	:	2 minutes
Inject time	:	0.1 minutes
Withdrawal time	:	0.2 minutes

GC Conditions

Column : RTX-1701 (Crossbond 14% cyanopropylphenyl
86% dimethylpolysiloxane)

Column dimensions : 60 metre length
0.53mm internal diameter
3.0 micron film thickness

Restrictor column : 5m length
0.25mm internal diameter

Carrier gas : Helium

Pressure : 30 psi

Oven temperature : 50°C

Injection temperature : 180°C

Detector : FID

Detector temperature : 250°C

Procedure

Place a Level 1 Calibration, a Level 2 Calibration and 2 vials for each sample into the headspace autosampler carousel and start the autosampler.

Calculation

Calculate the ratio of component peak area to n-propanol area in each of the chromatograms. Plot a graph of ratio against concentration for both calibrations and obtain the equation for the straight line. From this equation the concentration of each component in the sample can be calculated.



TSE/BSE-Certificate

116224 Sodium chloride EMPROVE® EXPERT Ph Eur,BP,JP,USP

The note for guidance EMA/410/01 Rev. 3 of the EC considers the requirements of raw materials used for human and veterinary medicinal products. The document introduces risk assessment into the regulatory compliance process for products derived from TSE/BSE-relevant animal species.

We certify that this product is manufactured without the use of raw materials of animal or human origin.

Sodium chloride is synthetically produced.

During processing the product does not come in contact with animal material.

Therefore, the product does not fall under the scope of the above-mentioned guideline and is not concerned by the TSE/BSE issue.

Dr. Jörg Schröder

Quality Services

This document has been produced electronically and is valid without a signature.

Date: 03-Mar-2020

Merck KGaA, Darmstadt, Germany

Corporation with General Partners
Frankfurter Str. 250
64293 Darmstadt, Germany
Phone +49 6151 72-0

Sigma-Aldrich Corporation

A subsidiary of Merck KGaA, Darmstadt, Germany
3050 Spruce Street
St. Louis, MO 63103, USA
Phone +1 (800) 521-8956 +1 (314) 771-5765

EMD Millipore Corporation

A subsidiary of Merck KGaA, Darmstadt, Germany
400 Summit Drive
Burlington, MA 1803, USA
Phone +1 (781) 533-6000


	<p>Calderdale & Huddersfield NHS Foundation Trust Pharmacy Manufacturing Unit Acre Mill Site</p>	
<p>Sterility Testing Validation Appendices</p>	<p>Appendix 7 Sterility Test Validation Report for Products</p>	<p>Revision: A</p>

**Sterility Testing -
Method Validation Report for**

Ketamine Hydrochloride Injection 15mg in 1ml

Section 1 – Product Information

Product Details			
Syspro Title:	Ketamine Hydrochloride Injection	Syspro Code:	KET01S
Batch Size:	1701	Container (Inc. Syspro code)	AC2 – 2ml Amp
Fill Volume:	1.2ml	Closure (Inc. Syspro code)	As Above
Sterility Testing Details			
Where Tested:	HPS		
Type of product:	Parenteral	Dose:	Single
Raw Materials Used and Grouping of Products			
Syspro Code	Syspro Title	Amount	Antimicrobial (AM) or Solvent(Sol)
R411	KETMINE HYDROCHLORIDE	43.238g	NO
R250	Sodium Chloride	22.5g	NO
Are any other products covered by this validation:		No	
If Yes, please state which products are covered and complete 'appendix 8' for each product:			
Syspro Title	Syspro Code	Appendix 8 completed (✓)	
N/A	N/A	N/A	

	Calderdale & Huddersfield NHS Foundation Trust Pharmacy Manufacturing Unit Acre Mill Site	
Sterility Testing Validation Appendices	Appendix 7 Sterility Test Validation Report for Products	Revision: A


Section 2 – Sterility Method Information

Sample Details (as per appendix 4)			
No. of Containers:	40	Volume per Media:	All content
Sterility Testing Method			
Steritest EZ Device (please tick):	Blue (mixed cellulose)	If using red or green, give justification:	QC0328/08
Steritest EZ Adaptors (please tick):	Ampoules / Collapsible bags	If deviating from recommended adaptor, give justification:	F22/79
Fluid (please tick):	Fluid A	If not using standard diluent, give justification:	QC0330/12 , QC0329/12
No of washes (please tick):	3 washes	If using 5 washes, give justification below: 2 x 50ml then 1 X 100ml per canister	THS/196 TSB/103

Section 3 - Results

Batch 1		Batch 2		Batch 3	
BN:	300218X	BN:	400218X	BN:	500218X
Session No:	STVAL2001	Session No:	STVAL2001	Session No:	STVAL2001
A.brasiliensis	G	A.brasiliensis	G	A.brasiliensis	G
B.subtilis	G	B.subtilis	G	B.subtilis	G
C.albicans	G	C.albicans	G	C.albicans	G
C.sporogenes	G	C.sporogenes	G	C.sporogenes	G
P.aeruginosa	G	P.aeruginosa	G	P.aeruginosa	G
S.aureus	G	S.aureus	G	S.aureus	G
Batch Outcome:	Pass	Batch Outcome:	Pass	Batch Outcome:	Pass

Section 4 - Approval

Approval			
Validation approved by:		Date:	15 JUNE 2020
	(QC Manager or Deputy)		

File Name and Path:	Y:\Validations 2020 sterility\ST VAL 3 Appendix 7 - Sterility Validation Report for Products for KET01S.docx	Save Date:	12/06/2020	Page Number:	Page 2 of 2
---------------------	--	------------	------------	--------------	-------------

LAL Validation Form - KT method

Product Name	Ketamine Hydrochloride Injection 15mg in 1ml				
Product Code	KETA07L				
Client	Huddersfield				
ELC	700 EU/ml	MVD	700,000x	CALCULATION REF	Client's email

PRELIMINARY TESTING - 10 FOLD DILUTIONS					
Reagent Lots					
LYSATE	519-08-934-T	CSE	170	LRW	AE28251284
Dilution	Spike Recovery				
Neat	None.				
10x	None.				
100x	75%				
1000x	105%				
10000x	137%	100000x 135%			
Analyst Ref	JMO	Pyros File	29/06/2020-JMO-A		

PRELIMINARY TESTING - 2FOLD DILUTIONS					
Reagent Lots					
LYSATE	519-08-934-T	CSE	170	LRW	AE28251284
Dilution	Spike Recovery				
1.0...x	None.				
2.0...x	8%				
4.0...x	10%				
8.0...x	24%				
16.0...x	4.6% 54%	640x 54% 1280x 63%			
Analyst Ref	IS	Pyros File	06/07/2020B		

VALIDATION TESTING								
Product Batch No.	Dilution Factor	Product Spike Recovery	Water Spike Recovery	Pyros File	Analyst Ref	Lysate Lot	CSE Lot	LRW Lot
300218X	1280...x	63%	117%	06/07/2020B	IS	519-08-934-T	170	AE28251284
500218X	1280...x	78%	123%	7/7/2020A	IS	519-08-934-T	170	AE28251284
400218X	1280...x	78%	123%	7/7/2020A	IS	519-08-934-T	170	AE28251284

pH CHECK		
	pH	Analyst Ref
Product at 1280...x dilution + lysate (1:1)	6.452	Am 0710712020 Am (6) 201

Other Requirements	
--------------------	--


v.3.1.1.

Quality Control North West

Title LAL Validation Form - KT Method

Issue Date: 9/12/14

Issued by: D Rigge

QC Lab Manager: 

	<p>Calderdale & Huddersfield NHS Foundation Trust Pharmacy Manufacturing Unit Acre Mill Site</p>	
<p>Sterility Testing Validation Appendices</p>	<p>Appendix 7 Sterility Test Validation Report for Products</p>	<p>Revision: A</p>

**Sterility Testing -
Method Validation Report for**

Morphine Sulphate Injection 10mg in 1ml

Section 1 – Product Information

Product Details				
Syspro Title:	Morphine Sulphate Injection		Syspro Code:	MOR19S
Batch Size:	2.5L	Container (Inc. Syspro code)	AC2 – 2ml Amp	
Fill Volume:	1.2ml	Closure (Inc. Syspro code)	As Above	
Sterility Testing Details				
Where Tested:	HPS			
Type of product:	Parenteral	Dose:	Single	
Raw Materials Used and Grouping of Products				
Syspro Code	Syspro Title	Amount	Antimicrobial (AM) or Solvent(Sol)	
R171	Morphine Sulphate	25.0g	NO	
R250	Sodium Chloride	22.5g	NO	
R089	Disodium Edetate	2.5g	YES	
Are any other products covered by this validation:		No		
If Yes, please state which products are covered and complete 'appendix 8' for each product:				
Syspro Title	Syspro Code	Appendix 8 completed (✓)		
N/A	N/A	N/A		

File Name and Path:	Y:\Validations 2020 sterility\ST VAL 3 Appendix 7 - Sterility Validation Report for Products for MOR19S STVAL2001.docx	Save Date:	24/07/2020	Page Number:	Page 1 of 2
---------------------	--	------------	------------	--------------	-------------

	Calderdale & Huddersfield NHS Foundation Trust Pharmacy Manufacturing Unit Acre Mill Site	
Sterility Testing Validation Appendices	Appendix 7 Sterility Test Validation Report for Products	Revision: A

Section 2 – Sterility Method Information

Sample Details (as per appendix 4)			
No. of Containers:	40	Volume per Media:	All content
Sterility Testing Method			
Steritest EZ Device (please tick):	Blue (mixed cellulose)	If using red or green, give justification:	QC0328/08
Steritest EZ Adaptors (please tick):	Ampoules / Collapsible bags	If deviating from recommended adaptor, give justification:	F22/79
Fluid (please tick):	Fluid A	If not using standard diluent, give justification:	QC0330/12 , QC0329/12
No of washes (please tick):	3 washes	If using 5 washes, give justification below: 2 x 50ml then 1 X 100ml per canister	THS/196 TSB/103

Section 3 - Results


Batch 1		Batch 2		Batch 3	
BN:	200217X	BN:	300217X	BN:	400217X
Session No:	STVAL2001	Session No:	STVAL2001	Session No:	STVAL2001
A.brasiliensis	G	A.brasiliensis	G	A.brasiliensis	G
B.subtilis	G	B.subtilis	G	B.subtilis	★
C.albicans	G	C.albicans	G	C.albicans	G
C.sporogenes	G	C.sporogenes	G	C.sporogenes	G
P.aeruginosa	G	P.aeruginosa	G	P.aeruginosa	G
S.aureus	G	S.aureus	G	S.aureus	G
Batch Outcome:	Pass	Batch Outcome:	Pass	Batch Outcome:	Pass

Section 4 – Approval



See OOS 2020/19

Sheet 1 of 2

Approval			
Validation approved by:		Date:	24 Jul 2020
	(QC Manager or Deputy)		

File Name and Path:	Y:\Validations 2020 sterility\ST VAL 3 Appendix 7 - Sterility Validation Report for Products for MOR19S STVAL2001.docx	Save Date:	24/07/2020	Page Number:	Page 2 of 2
---------------------	--	------------	------------	--------------	-------------



Calderdale & Huddersfield NHS Foundation Trust
Pharmacy Manufacturing Unit
Acre Mill Site



Sterility Testing
Validation Appendices

Appendix 7
Sterility Test Validation Report for Products

Revision: A

**Sterility Testing -
Method Validation Report for
Morphine Sulphate Injection 10mg in 1ml**

Section 1 – Product Information

Product Details			
Syspro Title:	Morphine Sulphate Injection		Syspro Code: MOR19S
Batch Size:	2.5L	Container (Inc. Syspro code)	AC2 – 2ml Amp
Fill Volume:	1.2ml	Closure (Inc. Syspro code)	As Above
Sterility Testing Details			
Where Tested:	HPS		
Type of product:	Parenteral	Dose:	Single
Raw Materials Used and Grouping of Products			
Syspro Code	Syspro Title	Amount	Antimicrobial (AM) or Solvent(Sol)
R171	Morphine Sulphate	25.0g	NO
R250	Sodium Chloride	22.5g	NO
R089	Disodium Edetate	2.5g	YES
Are any other products covered by this validation:		No	
If Yes, please state which products are covered and complete 'appendix 8' for each product:			
Syspro Title	Syspro Code	Appendix 8 completed (✓)	
N/A	N/A	N/A	

	Calderdale & Huddersfield NHS Foundation Trust Pharmacy Manufacturing Unit Acre Mill Site	
Sterility Testing Validation Appendices	Appendix 7 Sterility Test Validation Report for Products	Revision: A


Section 2 – Sterility Method Information

Sample Details (as per appendix 4)			
No. of Containers:	40	Volume per Media:	All content
Sterility Testing Method			
Steritest EZ Device (please tick):	Blue (mixed cellulose)	If using red or green, give justification:	QC0328/06
Steritest EZ Adaptors (please tick):	Ampoules / Collapsible bags	If deviating from recommended adaptor, give justification:	F22/82
Fluid (please tick):	Fluid A	If not using standard diluent, give justification:	QC0330/14, QC0329/14
No of washes (please tick):	3 washes	If using 5 washes, give justification below: 2 x 50ml then 1 X 100ml per canister	THS/199 TSB/105

Section 3 - Results

Batch 1		Batch 2		Batch 3	
BN:	400217X	BN:		BN:	
Session No:	STVAL2002	Session No:		Session No:	
A.brasiliensis		A.brasiliensis		A.brasiliensis	
B.subtilis	G	B.subtilis		B.subtilis	
C.albicans		C.albicans		C.albicans	
C.sporogenes		C.sporogenes		C.sporogenes	
P.aeruginosa		P.aeruginosa		P.aeruginosa	
S.aureus		S.aureus		S.aureus	
Batch Outcome:	Pass	Batch Outcome:		Batch Outcome:	

Section 4 – Approval Sheet 2 of 2

Approval			
Validation approved by:		Date:	24 Jul 2020
	(QC Manager or Deputy)		

File Name and Path:	Y:\Validations 2020 sterility\ST VAL 3 Appendix 7 - Sterility Validation Report for Products for MOR19S STVAL2002.docx	Save Date:	24/07/2020	Page Number:	Page 2 of 2
---------------------	--	------------	------------	--------------	-------------

LAL Validation Form - KT method

Product Name	Morphine Sulphate Injection 10mg in 1ml				
Product Code	MORP27L				
Client	Huddersfield				
ELC	700 EU/mL	MVD	700,000 x	CALCULATION REF	Client's email

PRELIMINARY TESTING - 10 FOLD DILUTIONS					
Reagent Lots					
LYSATE	519-08-934-T	CSE	170	LRW	AE28251284
Dilution	Spike Recovery				
Neat	None				
10x	14%				
100x	134%				
1000x	150%				
10000x	164% 100,000x 155%				
Analyst Ref	JMD	Pyros File	29/06/2020 - JMD - A		

PRELIMINARY TESTING - 2FOLD DILUTIONS					
Reagent Lots					
LYSATE	519-08-934-T	CSE	170	LRW	AE28251284
Dilution	Spike Recovery				
100...x	7%				
200...x	35%				
400...x	82%				
800...x	103%				
.....x					
Analyst Ref	IP	Pyros File	06/07/2020A		

VALIDATION TESTING								
Product Batch No.	Dilution Factor	Product Spike Recovery	Water Spike Recovery	Pyros File	Analyst Ref	Lysate Lot	CSE Lot	LRW Lot
200217X 200217 26/7/2020	80...x	103%	147%	06/07/2020 A	IP	519-08-934-T	170	AE2825 1284
300217X	80...x	67%	117%	06/07/2020 B	IP	519-08-934-T	170	AE2825 1284
400217X	80...x	66%	117%	06/07/2020 B	IP	519-08-934-T	170	AE2825 1284

pH CHECK		
Product at ...x dilution + lysate (1:1)	pH	Analyst Ref
Product at 80...x dilution + lysate (1:1)	6.421	AM 0710712020 AM (6)201

Other Requirements	
--------------------	--

V.310

Quality Control North West

Title LAL Validation Form - KT Method

Issue Date: 9/12/14

Issued by: D Rigge

QC Lab Manager: 



Product Code	MOR19S	Batch number	200217X	DOM	17-Feb-20
Product Name	Morphine Sulphate Injection				
Strength	10mg/mL	Pack size		1mL in 2mL ampoule	
Stability Protocol Reference	SLJ_MOR19S_001_results				
Duration of Stability Study	24M				
Timepoints required	0,3,6,9,12,18,24M				
Storage Condition(s)	25°C/60%RH				

Test	Specification		Timepoint/null date										
			T=0	3M	6M	9M	12M	15M	18M	24M			
Examination	Complies		1st Filled	Random									
pH	Record		Complies	Complies	Complies	Complies							
Identification of Morphine Sulphate	1. Complies 2. Complies		4.58	4.63	4.66	4.54							
Morphine Sulphate (10mg/mL)	Release: 9.5-10.5mg/mL (95.0-105.0% nominal) Over Shelf Life: 9.25-10.75mg/mL (92.5 - 107.5%)		Complies	Complies									
Known/unknown related substances (%wt API)	NGT 0.5% wt API, not more than one greater than 0.2% with	IMP A	10.13	10.12	10.15	10.09							
		IMP B	0.05	0.03	ND	0.03							
		IMP C	ND	ND	ND	ND							
		IMP D	0.07	0.06	0.03	0.03							
		IMP E	0.05	0.04	0.02	0.01							
		IMP F	0.04	ND	ND	ND							
		Unknown @ R13.0	0.04	0.03	ND	0.01							
Total known/unknown related substances (%wt API)	NGT 2.0 %		Unknown @ R15.0	0.06	ND	0.00							
Sterility	Complies		0.31	0.19	0.05	0.08	0.00	0.00	0.00	0.00	0.00	0.00	
Particle Counts	10µm ≤ 6000/container		Complies										
	25µm ≤ 600/container		28.5										
Bacterial Endotoxins	17 EU/mg		0.7										

Method reference MOR19S version

ND = None detected
NT = Not Tested



Product Code	MOR19S	Batch number	200217X	DOM	17-Feb-20
Product Name	Morphine Sulphate Injection				
Strength	10mg/mL	Pack size	1mL in 2mL ampoule		
Stability Protocol Reference	SLJ_MOR19S_001_results				
Duration of Stability Study	24M				
Timepoints required	3M, 6M, 9M, 12M				
Storage Condition(s)	30°C/65%RH				

Test	Specification	Timepoint/pull date					
		T=0	3M	6M	9M	12M	
Examination	Complies	Complies	Complies	Complies	Complies	Complies	
pH	Record	4.58	4.63	4.68			
Identification of Morphine Sulphate	1. Complies 2. Complies	Complies					
Morphine Sulphate (10mg/mL)	Release: 9.5-10.5mg/mL (95.0-105.0% nominal) Life: 9.25-10.75mg/mL (92.5 - 107.5%)	10.13	10.12	10.09			
Known/unknown related substances (%wrt API)	NGT 0.5% wrt API , with not more than one greater than 0.2%	IMP A	0.05	0.03	0.03		
		IMP B	ND	ND	0.02		
		IMP C	0.07	0.03	0.03		
		IMP E	0.05	0.04	0.01		
		IMP F	0.04	ND	ND		
		Unknown @ RT 3.9	0.04	0.03	0.01		
Total known/unknown related substances (%wrt API)	NGT 2.0 %	0.31	0.03	0.09	0.00	0.00	
Sterility	Complies	Complies					
Particle Counts	10µm ≤ 6000/container	28.5					
	25µm ≤ 600/container	0.7					
Bacterial Endotoxins	17 EU/mg						

Method reference MOR19S version

ND = None detected

NT= Not Tested



Product Code	MOR19S	Batch number	200217X	17-Feb-20
Product Name	Morphine Sulphate Injection			
Strength	10mg/mL	Pack size	2mL	
Stability Protocol Reference	SLJ_MOR19S_001_results			
Duration of Stability Study	24M			
Timepoints required	1M, 2M, 3M, 6M			
Storage Condition(s)	40°C/75%RH			

Test	Specification		Timepoint/pull date					
			T=0		1M	2M	3M	6M
			Ist Filled	Random				
Examination	Complies		Complies	Complies	Complies	Complies	Complies	Complies
pH	Record		4.58	4.63	4.73	4.68	4.65	4.68
Identification of Morphine Sulphate	1. Complies 2. Complies		Complies	Complies				
Morphine Sulphate (10mg/mL)	Release: 9.5-10.5mg/mL (95.0-105.0% nominal) Over Shelf Life: 9.25-10.75mg/mL (92.5 - 107.5%)		10.13	10.12	10.05	10.28	10.14	10.06
Known/unknown related substances (%wrt API)	NGT 0.5% wrt API, with not more than one greater than 0.2%	IMP A	0.05	0.03	0.04	0.09	ND	0.03
		IMP B	ND	ND	ND	0.01	0.02	0.03
		IMP C	0.07	0.09	0.03	ND	0.03	0.03
		IMP E	0.05	0.04	0.01	0.02	0.01	0.01
		IMP F	0.04	ND	ND	ND	ND	ND
		Unknown @ RT 3.9	0.04	0.03	0.05	0.04	ND	0.01
		Unknown @ RT 5.0	0.06	ND	ND	ND	ND	0.00
		Unknown @ RT 8.0	ND	ND	ND	0.05	ND	ND
Total known/unknown related substances (%wrt API)	NGT 2.0 %		0.31	0.19	0.13	0.21	0.06	0.12
Sterility	Complies							
Particle Counts	10µm ≤ 6000/container		28.5					
	25µm ≤ 600/container		0.7					
Bacterial Endotoxins	17 EU/mg							

Method reference MOR19S version

1

ND = None detected

NT= Not Tested



Product Code	KET01S	Batch number	300218X	DOM	18-Feb-20
Product Name	Ketamine Injection				
Strength	15mg/mL	Pack size	1mL in 2mL ampoule		
Stability Protocol Reference	SLJ_KET01S_001_results				
Duration of Stability Study	24M				
Timepoints required	0,3,6,9,12,18,24M				
Storage Condition(s)	25°C/60%RH				

Test	Specification	Timepoint/pull date														
		T=0		1M	2M	3M	6M	9M	12M	15M	18M	24M				
		Ist	Random	Complies	Complies	Complies	Complies	Complies	Complies	Complies	Complies	Complies	Complies	Complies	Complies	Complies
Examination	Complies	Complies	Complies	Complies	Complies	Complies	Complies	Complies	Complies	Complies	Complies	Complies	Complies	Complies	Complies	Complies
pH	Record	4.51	4.58			4.70				4.77						
Identification of Ketamine	1. Complies 2. Complies	Complies	Complies													
Ketamine (15mg/mL)	14.25-15.75mg/mL 95.0-105.0% nominal	15.55	15.47	14.94	14.78	15.25	15.46									
Known/unknown related substances (%wrt API)	NGT 0.5% wrt API, with not more than one greater than 0.25%	0.16	0.10			ND	ND									
Total known/unknown related substances (%wrt API)	NGT 1.0 %	0.42	0.41	0.40	0.42	0.32	0.20									
Sterility	Complies	0.58	0.51	0.40	0.42	0.32	0.20									
Particle Counts	Complies															
	10µm ≤6000/container	9.1														
	25µm ≤600/container	0.4														

Method reference KET01S version

ND = None detected

NT= Not Tested



Product Code	KET01S	Batch number	300218X	DOM	18-Feb-20
Product Name	Ketamine Injection				
Strength	15mg/mL	Pack size	1mL in 2mL ampoule		
Stability Protocol Reference	SLJ_KET01S_001_results				
Duration of Stability Study	24M				
Timepoints required	3M, 6M, 9M, 12M				
Storage Condition(s)	30°C/65%RH				

Test	Specification	Timepoint/pull date					
		T=0		3M	6M	9M	12M
Examination	Complies	Ist	Random				
pH	Record	Complies	Complies	Complies	Complies		
Identification of Ketamine	1. Complies 2. Complies	4.51	4.58	4.71	4.81		
Ketamine (15mg/mL)	14.25-15.75mg/mL 95.0-105.0% nominal	Complies	Complies				
Known/unknown related substances (%wrt API)	NGT 0.5% wrt API, with not more than one greater than 0.25%	15.55	15.47	15.39	15.41		
Total known/unknown related substances (%wrt API)	NGT 1.0 %	0.116	0.1	ND	ND		
Sterility	Complies	0.42	0.41	0.32	0.21		
Particle Counts	10µm ≤ 6000/container	0.58	0.51	0.32	0.21		
	25µm ≤ 600/container						
			9.1				
			0.4				

Method reference KET01S version

ND = None detected

NT= Not Tested



Product Code	KET01S	Batch number	300218X	DOM	18-Feb-20
Product Name	Ketamine Injection				
Strength	15mg/mL	Pack size	1mL in 2mL ampoule		
Stability Protocol Reference	SLJ_KET01S_001_results				
Duration of Stability Study	24M				
Timepoints required	1M, 2M, 3M, 6M				
Storage Condition(s)	40°C/75%RH				

Test	Specification	Timepoint/pull date					
		T=0		1M	2M	3M	6M
Examination	Complies	Complies	Complies	Complies	Complies	Complies	Complies
pH	Record	4.51	4.58	4.81	4.94	4.78	4.86
Identification of Ketamine	1. Complies 2. Complies	Complies	Complies				
Ketamine (15mg/mL)	14.25-15.75mg/mL 95.0-105.0% nominal	15.55	15.47	15.11	14.53	15.32	15.26
Known/unknown related substances (%wrt API)	NGT 0.5% wrt API, with not more than one greater than 0.25%	RT 7.6	0.10			ND	ND
		Imp A	0.41	0.41	0.43	0.33	0.22
Total known/unknown related substances (%wrt API)	NGT 1.0 %	0.58	0.51	0.41	0.43	0.33	0.22
Sterility	Complies						
Particle Counts	10µm ≤ 6000/container	9.1					
	25µm ≤ 600/container	0.4					

Method reference KET01S version 1

ND = None detected

NT = Not Tested

AkzoNobel
Chelates and Micronutrients



Endorsement Letter

Deventer, October 27, 2017

TO WHOM IT MAY CONCERN

Herewith we confirm that in the production of

all DISSOLVINE[®] products

produced by

Akzo Nobel Functional Chemicals

no material of animal origin has been used during the whole production process. This also includes materials used as reagents (e.g. bovine serum albumin, enzymes, culture media incl. those to prepare working cell banks or new master cell banks)"

Also the plant equipment used does not come in contact with any material of animal origin.

Based on these data we declare that all Dissolvine products are **TSE** (including **BSE**) free.

Yours sincerely,

J. Feddema
Technical Service
Chelates and Micronutrients
Ethylene and Sulfur Derivatives

Akzo Nobel Functional Chemicals B.V.
P.O. Box 10
7400 AA Deventer
the Netherlands

The information presented herein is true and accurate to the best of our knowledge, but without any guarantee unless explicitly given. Since the conditions of use are beyond our control, we disclaim any liability, including for patent infringement, incurred in connection with the use of these products, data or suggestions.

® Our brand name and the AkzoNobel device are trademarks of the AkzoNobel group of companies
© Akzo Nobel Functional Chemicals B.V.

Arona Pharmaceuticals Ltd
Unit 14, Apollo Office Court
Redcliffe Road
Gawcott
Buckingham
MK18 4DF
MHRA Registration Ref: API42376



CU Chemie Uetikon GmbH
Raiffeisenstr. 4
D-77933 Lahr
Germany

TO WHOM IT MAY CONCERN

Lahr, August 21, 2018

CONFIRMATION
of Material Origin for BSE/TSE Risk Evaluation

We hereby confirm, that our API

Ketamine Hydrochloride (product code: K1350)

is produced by chemical synthesis. It is not derived from any animal origin. It is therefore out of the scope of the current Ph. Eur. monograph <5.2.8> "Minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products".

There are validated cleaning procedures in place to avoid cross contamination. These procedures also minimize any risk of potential carry over of residues of animal origin materials which came into contact with the equipment before using it for the manufacture of the above mentioned material.

Sincerely,

CU Chemie Uetikon GmbH

i.A. Alina Wetternek
Regulatory Affairs Specialist

CU Chemie Uetikon GmbH

Raiffeisenstr. 4
77933 Lahr/Germany
Tel +49 7821 585 0
Fax +49 7821 585 230
info@uetikon.com
www.uetikon.com

Commerzbank AG

Account: 742242800
Sort Code: 680 800 30
Branch: Freiburg
BIC/SWIFT DRESDEFF680
IBAN DE65 6808 0030 0742 2428 00

Management Board: Frédéric Desdouts
Registered Office: Lahr/Schwarzwald
Court of Registration: Freiburg HRB 390945
VAT Nr. DE142359210



Johnson Matthey
Inspiring science, enhancing life

Macfarlan Smith Limited
Wheatfield Road
Edinburgh
EH11 2QA

T +44 (0) 131 337 2434
F +44 (0) 131 337 4436

**LETTER OF DECLARATION OF MANUFACTURE REGARDING
THE USE OF MATERIAL OF HUMAN OR ANIMAL ORIGIN
INCLUDING SUBSTANCES AT RISK OF TRANSMITTING AGENTS OF ANIMAL SPONGIFORM
ENCEPHALOPATHIES**

Macfarlan Smith Limited hereby confirms compliance with the CPMP/CVMP Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products (EMA/410/01 Rev 3, July 2011) for the manufacture of the APIs listed on the following page.

We confirm that:

- Materials used in the manufacturing processes are not of human or animal origin.
- Facilities for the processing and handling of APIs and intermediates are not used for handling components of human or animal origin.
- All non-direct process related materials such as oils, greases and cleaning agents are not of human or animal origin.

18-JULY-2019.

Dr Gavin Matthew CBIol MRSB
Director Quality Assurance / Quality Control, Scotland
Macfarlan Smith Limited

JM

Alfentanil Hydrochloride
Apomorphine Hydrochloride
Buprenorphine
Buprenorphine Hydrochloride
Cocaine
Cocaine Hydrochloride
Codeine
Codeine Sulfate
Codeine Phosphate
Diamorphine
Diamorphine Hydrochloride
Dihydrocodeine Hydrogen Tartrate
Diprenorphine
Etorphine
Fentanyl
Fentanyl Citrate
Hydromorphone Hydrochloride
Methylphenidate Hydrochloride
Morphine Hydrochloride
Morphine Sulfate
Morphine Tartrate
Naloxone Hydrochloride
Naltrexone Hydrochloride
Oxycodone Hydrochloride
Pholcodine
Remifentanil Hydrochloride
Sufentanil Citrate